Erick Vazquez receives the Pfizer vaccine during an event to inoculate about 500 health care workers and adults over the age of 65 against COVID-19 put on by the Labor Community Services, the Los Angeles Federation of Labor and St. Johns Well Child and Family Center coined Labor of Love, in Pico Union, Feb. 13, 2021 in Los Angeles, CA.
Dania Maxwell | Los Angeles Times | Getty Images
The Food and Drug Administration said Monday that modified Covid-19 vaccines against new, emerging variants may be authorized without the need for lengthy clinical trials.
The new guidance, released in a 24-page document on the FDA’s website, would clear the new vaccines as an amendment to a company’s originally approved emergency use application, according to the FDA. The company would need to submit new data that shows the modified vaccine produces a similar immune response and is safe, similar to the process for annual flu vaccines.
“Preliminary reports from clinical trials evaluating COVID-19 vaccine candidates in multiple countries including South Africa have added to concerns that vaccine efficacy against the B.1.351 variant may be lower than against the original virus,” the agency wrote in the document, referring to the strain found in South Africa. “Thus, there is an urgent need to initiate development and evaluation of vaccines against these SARSCoV-2 variants.”
The updated guidance comes as U.S. health officials, including White House Chief Medical Advisor Dr. Anthony Fauci, are concerned the virus potentially could mutate enough to evade the protection of current vaccines and reverse the progress made on the pandemic.
In recent weeks, officials have pushed Americans to get vaccinated as quickly as possible before potentially new and even more dangerous variants of the virus emerge.
As of Sunday, the Centers for Disease Control and Prevention has identified 1,661 cases of the B.1.1.7 variant first identified in the U.K. The agency has identified 22 cases of the B.1.351 strain from South Africa as well as five cases of P.1, a variant first identified in Brazil.
The FDA authorized Pfizer’s and Moderna’s vaccines for emergency use in December, and the two drugmakers have since announced plans to modify their shots to target new variants. The guidance could accelerate the regulatory review process for the vaccines.
This is a developing story. Please check back for updates.
Source link
This article originally appeared on www.cnbc.com
